SELLAS LIFE SCIE

SLS NASDAQ
0.1470
-0.0022
-1.47%
After Hours: 0.1471 +0.0001 +0.07% 19:34 08/23 EDT
Open
0.1495
Prev Close
0.1492
High
0.1510
Low
0.1445
Volume
7.91M
Avg Vol (3M)
28.39M
52 Week High
2.460
52 Week Low
0.1021
% Turnover
3.49%
Market Cap
33.30M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers SELLAS LIFE SCIE SLS stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

SELLAS Life Sciences Group, Inc., formerly Galena Biopharma, Inc., is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company's NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company's therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient's own immune system.
MORE >

Recently

Name
Price
%Change